Relay Therapeutics, Inc.
RLAY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.51 | 0.18 | -0.16 |
| FCF Yield | -42.66% | -22.56% | -14.23% | -2.67% |
| EV / EBITDA | -1.35 | -3.37 | -5.16 | -11.99 |
| Quality | ||||
| ROIC | -45.08% | -45.56% | -28.77% | -36.92% |
| Gross Margin | -3,052.20% | 100.00% | -17,496.31% | -5,492.21% |
| Cash Conversion Ratio | 0.74 | 0.88 | 0.79 | 0.20 |
| Growth | ||||
| Revenue 3-Year CAGR | 93.51% | 103.55% | -74.44% | – |
| Free Cash Flow Growth | 17.51% | -27.62% | -206.32% | 25.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 0.24 | 0.31 | 1.16 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.34 | -0.01 |
| Cash Conversion Cycle | -941.69 | -638.07 | 1,514.78 | -63,641.65 |